"BMS acknowledge the progress made in rare cancers through MRFF grants and budget announcements for rare diseases (including cancers). However, we challenge that average approval listing delay of 320 days is not good enough and believe we all need to strive to do better," said the company in a statement.

Latest Video
New Stories
-
Health spending under increasing pressure, as department looks to offsets
July 9, 2025 - - Latest News -
AusBiotech welcomes 27 new members in first half of 2025
July 9, 2025 - - Latest News -
Consortium established to co-design new telehealth standards
July 8, 2025 - - Latest News -
South Australia expands flu vax availability in response to record outbreak
July 8, 2025 - - Latest News -
MedAdvisor restates focus on US following completion of ANZ business sale
July 8, 2025 - - Latest News -
More companies are exercising their rights, and they are perfectly entitled
July 7, 2025 - - Latest News -
Neurotech’s Rett Syndrome trial results published in scientific journal
July 7, 2025 - - Australian Biotech